CBD
Companhia Brasileira de Distribuicao
stock NYSE

ProText Mobility, Inc. (OTC: TXTM) – Stock Analysis
Important opening note: TXTM is a micro-cap stock listed on the OTC Pink Sheets (not a major exchange) with a share price in the extremely low single-cent range (about $0.005 as of early July 2026). The company has no verified, audited (PCAOB) financial statements, no reported revenue, EBITDA, or net income in standardized databases, and a track record of company-issued press releases with unusually promotional language (e.g., claims of a “$505 million debt-free balance sheet,” “tokenization,” “uplisting”). These are hallmarks often seen in highly speculative/pump-like OTC stocks. The analysis below follows the requested structure, but should be read with significant caveats.
1. Company Overview
Business model: ProText Mobility is a biotech company developing a hemp/cannabidiol (CBD)-cannabis medicines platform for the legal cannabis industry, using live plant extraction processes and technologies. The company engages in research, testing, and development of natural ingredients for nutraceutical and pharmaceutical applications via proprietary plant extraction technology, and operates subsidiaries including Plandai Biotechnology, Cannabis Biosciences, and RSAMMD Acquisitions.
More recent company announcements also describe a pivot toward “real-world-asset” tokenization, research into “kettle” and nanotechnology, and plans for uplisting via a preliminary valuation with Deloitte. The company also states it has a debt-free, non-dilutive capital structure, no management salaries, and no reverse split.
Markets and competitive position: The company operates in the broad field of botanical/CBD nutraceuticals as well as (recently) tokenized assets — both highly competitive and partly unregulated/speculative niches. There is no publicly available documentation of commercial scaling, product launches, or market share.
Key figures:
|Metric |Value |
|-----------------------------|-------------------------------------------------------------------------------|
|Share price (early July 2026)|approx. $0.005–0.007 |
|Market cap |approx. $12–43 million (fluctuates significantly depending on measurement date)|
|Shares outstanding |approx. 1.95 billion (other sources cite figures in the billions) |
|Revenue (ttm) |Not reported / “–” |
|EBITDA |Not reported |
|Net income |Profit margin 0.00% |
|P/E, EV/EBITDA |Not meaningfully calculable (no earnings/revenue) |
|Debt |Company claims to be debt-free |
|52-week range |$0.0005–$0.0092 |
There are therefore effectively none of the classic valuation multiples (P/E, EV/EBITDA) available, because the company has not reported revenue or earnings in a format that auditors/databases can verify.
2. Strengths & Risks
Potential positive factors:
• The company claims to have completed IFRS-audited financials for 2022 and 2023 and is working on 2024 filings with a view to a possible SEC Form 10.
• The company’s chairman has repeatedly purchased shares on the open market and has never sold, which could be interpreted as a signal of ownership alignment.
• Exposure to CBD/botanical nutraceuticals and “RWA” tokenization, both themes with potential future interest.
Critical risk factors:
• No verifiable revenue or earnings. The company effectively has no operational substance to support a fundamental valuation.
• Extreme dilution history and share price level (sub-cent), typical of “shell” companies.
• Unusually promotional IR communications (e.g., the claim of a $505 million balance sheet for a company with under $50 million in market cap and no reported revenue) is a significant red flag.
• The company is a former delinquent SEC filer now voluntarily resuming filings — indicating a period without ongoing, verified disclosure.
• No independent, third-party-confirmed audit is publicly available in standard databases (Yahoo/CNBC/Seeking Alpha all show blank fields for earnings).
• Very low liquidity and high volatility make the position difficult to trade without significant price impact.
• High risk of further dilution, corporate changes, or total loss of value.
3. Scenarios
Since there is no analyst consensus, real earnings estimates, or a functioning valuation model for TXTM, the scenarios below are not based on fundamental multiples, but on qualitative, speculative assumptions typical for this type of OTC stock. The probabilities are estimates, not statistically grounded figures.
🐻 Bear Case (probability: ~55–60%)
Triggering factors: Promised real financial filings fail to materialize, “uplisting” plans and the Deloitte valuation don’t lead to anything concrete, continued absence of revenue, or the company loses its OTC status/becomes further delinquent.
Price trajectory: Decline toward or below the 52-week low (approx. $0.0005–0.002), potentially total loss of value.
Time horizon: 6–18 months.
📊 Base Case (probability: ~30–35%)
Realistic expectations: The company continues as a low-liquidity, speculative OTC shell with sporadic press releases, without meaningful real commercial revenue. The price remains largely sideways with high volatility, driven by news flow rather than fundamentals.
Price trajectory: Continued trading in the range of approx. $0.003–0.010.
Time horizon: 12 months.
🐂 Bull Case (probability: ~10–15%)
What needs to go right: The company actually delivers audited financials accepted by the market, successfully completes an uplisting to a more regulated exchange, and one of the mentioned LOIs/partnerships (e.g., TruLeaf) generates real, verifiable revenue.
Price trajectory: Significant price increase (several multiples of the current price), but from a very low base and with continued high dilution risk.
Time horizon: 12–24 months.
Overall assessment: TXTM appears to be an extremely high-risk, speculative OTC micro-cap without verifiable fundamental data to support a traditional valuation. This is not investment advice — I am not a financial advisor or a licensed analyst in a legal sense, and any decision should be based on your own due diligence, including review of the company’s actual SEC/OTC filings, as well as potential guidance from a licensed financial advisor.

Exactly that brother I mean, that’s literally all you need, use the the GEX data and composite volume profiles with the heat map on book map and see if the levels match up and then just trade the reversal from there and then if you really wanna get crazy you can use a footprint chart and look for a CBD divergence or look for a volume spike and it’s literally just once you see exhaustion on buyers to sellers or sellers to buyers, you know you’re in the money, especially if that’s out of value area lower evaluate area higher a POC or a high volume note a low volume node for a zero print like you know price is just gonna run through that shit so you’re right on the money, bro.
I trade on the 32nd and give myself a super tight stop. I want to see price continue in my direction if I’m right and I move to break even quickly so if I’m wrong, I’m wrong and then I try it again and again and again and again and eventually that train will leave the station and go where I wanted to go and I’ll collect my 150 ticks and I’ll call it a day but I do not limit myself to a certain number of trades nor do I have a daily loss limit unless I’m up a considerable amount then I’ll put it on there, but that’s only if like a runner ran like a 1 to 10 RR or something insane

I don’t have one. I will never have one if I made any course it would be around the mindset because the mindset is what was the real key for me being profitable truly. It’s the manifestation aspect. It has nothing to do with trading. It has everything to do with self-concept and your belief about money and making money reading candles on a chart and reading overflow and get Data Gamma Vanna, positive gamma negative gamma CBD divergence is delta‘s standard deviations, etc. none of that shit is hard but your belief about withdrawing the money and putting it in your bank account and keeping it in rinsing and repeating and doing it over and over and over again and the reason you can’t follow a set of rules or stick to a system or jump from strategy strategy is because of a deep proceeded wound that is in yourself. Once you can heal that and be completely OK with who you are what you are doing where you are going in the belief within yourself of the money you are capable of making I promise you, I swear to you, your entire life will open up and things will change for you in ways. You have never seen that is the true sauce. It isn’t learning a system. It isn’t copying traitors. It isn’t signal boarding. It is strictly believing in a real reality that doesn’t exist yet, but acting as if you have that but that’s profitability whether that’s rinsing these proper whether that’s being a live trait or whatever it is that you want you need to identify that and then find the blocks that are inhibiting you from getting there and then once you find those blocks, heal them and replace them with the opposite thinking and that will yield you in ROY you cannot even qualify, brother

ProText Mobility, Inc. (OTC: TXTM) – Stock Analysis
Important opening note: TXTM is a micro-cap stock listed on the OTC Pink Sheets (not a major exchange) with a share price in the extremely low single-cent range (about $0.005 as of early July 2026). The company has no verified, audited (PCAOB) financial statements, no reported revenue, EBITDA, or net income in standardized databases, and a track record of company-issued press releases with unusually promotional language (e.g., claims of a “$505 million debt-free balance sheet,” “tokenization,” “uplisting”). These are hallmarks often seen in highly speculative/pump-like OTC stocks. The analysis below follows the requested structure, but should be read with significant caveats.
1. Company Overview
Business model: ProText Mobility is a biotech company developing a hemp/cannabidiol (CBD)-cannabis medicines platform for the legal cannabis industry, using live plant extraction processes and technologies. The company engages in research, testing, and development of natural ingredients for nutraceutical and pharmaceutical applications via proprietary plant extraction technology, and operates subsidiaries including Plandai Biotechnology, Cannabis Biosciences, and RSAMMD Acquisitions.
More recent company announcements also describe a pivot toward “real-world-asset” tokenization, research into “kettle” and nanotechnology, and plans for uplisting via a preliminary valuation with Deloitte. The company also states it has a debt-free, non-dilutive capital structure, no management salaries, and no reverse split.
Markets and competitive position: The company operates in the broad field of botanical/CBD nutraceuticals as well as (recently) tokenized assets — both highly competitive and partly unregulated/speculative niches. There is no publicly available documentation of commercial scaling, product launches, or market share.
Key figures:
|Metric |Value |
|-----------------------------|-------------------------------------------------------------------------------|
|Share price (early July 2026)|approx. $0.005–0.007 |
|Market cap |approx. $12–43 million (fluctuates significantly depending on measurement date)|
|Shares outstanding |approx. 1.95 billion (other sources cite figures in the billions) |
|Revenue (ttm) |Not reported / “–” |
|EBITDA |Not reported |
|Net income |Profit margin 0.00% |
|P/E, EV/EBITDA |Not meaningfully calculable (no earnings/revenue) |
|Debt |Company claims to be debt-free |
|52-week range |$0.0005–$0.0092 |
There are therefore effectively none of the classic valuation multiples (P/E, EV/EBITDA) available, because the company has not reported revenue or earnings in a format that auditors/databases can verify.
2. Strengths & Risks
Potential positive factors:
• The company claims to have completed IFRS-audited financials for 2022 and 2023 and is working on 2024 filings with a view to a possible SEC Form 10.
• The company’s chairman has repeatedly purchased shares on the open market and has never sold, which could be interpreted as a signal of ownership alignment.
• Exposure to CBD/botanical nutraceuticals and “RWA” tokenization, both themes with potential future interest.
Critical risk factors:
• No verifiable revenue or earnings. The company effectively has no operational substance to support a fundamental valuation.
• Extreme dilution history and share price level (sub-cent), typical of “shell” companies.
• Unusually promotional IR communications (e.g., the claim of a $505 million balance sheet for a company with under $50 million in market cap and no reported revenue) is a significant red flag.
• The company is a former delinquent SEC filer now voluntarily resuming filings — indicating a period without ongoing, verified disclosure.
• No independent, third-party-confirmed audit is publicly available in standard databases (Yahoo/CNBC/Seeking Alpha all show blank fields for earnings).
• Very low liquidity and high volatility make the position difficult to trade without significant price impact.
• High risk of further dilution, corporate changes, or total loss of value.
3. Scenarios
Since there is no analyst consensus, real earnings estimates, or a functioning valuation model for TXTM, the scenarios below are not based on fundamental multiples, but on qualitative, speculative assumptions typical for this type of OTC stock. The probabilities are estimates, not statistically grounded figures.
🐻 Bear Case (probability: ~55–60%)
Triggering factors: Promised real financial filings fail to materialize, “uplisting” plans and the Deloitte valuation don’t lead to anything concrete, continued absence of revenue, or the company loses its OTC status/becomes further delinquent.
Price trajectory: Decline toward or below the 52-week low (approx. $0.0005–0.002), potentially total loss of value.
Time horizon: 6–18 months.
📊 Base Case (probability: ~30–35%)
Realistic expectations: The company continues as a low-liquidity, speculative OTC shell with sporadic press releases, without meaningful real commercial revenue. The price remains largely sideways with high volatility, driven by news flow rather than fundamentals.
Price trajectory: Continued trading in the range of approx. $0.003–0.010.
Time horizon: 12 months.
🐂 Bull Case (probability: ~10–15%)
What needs to go right: The company actually delivers audited financials accepted by the market, successfully completes an uplisting to a more regulated exchange, and one of the mentioned LOIs/partnerships (e.g., TruLeaf) generates real, verifiable revenue.
Price trajectory: Significant price increase (several multiples of the current price), but from a very low base and with continued high dilution risk.
Time horizon: 12–24 months.
Overall assessment: TXTM appears to be an extremely high-risk, speculative OTC micro-cap without verifiable fundamental data to support a traditional valuation. This is not investment advice — I am not a financial advisor or a licensed analyst in a legal sense, and any decision should be based on your own due diligence, including review of the company’s actual SEC/OTC filings, as well as potential guidance from a licensed financial advisor.

Exactly that brother I mean, that’s literally all you need, use the the GEX data and composite volume profiles with the heat map on book map and see if the levels match up and then just trade the reversal from there and then if you really wanna get crazy you can use a footprint chart and look for a CBD divergence or look for a volume spike and it’s literally just once you see exhaustion on buyers to sellers or sellers to buyers, you know you’re in the money, especially if that’s out of value area lower evaluate area higher a POC or a high volume note a low volume node for a zero print like you know price is just gonna run through that shit so you’re right on the money, bro.
I trade on the 32nd and give myself a super tight stop. I want to see price continue in my direction if I’m right and I move to break even quickly so if I’m wrong, I’m wrong and then I try it again and again and again and again and eventually that train will leave the station and go where I wanted to go and I’ll collect my 150 ticks and I’ll call it a day but I do not limit myself to a certain number of trades nor do I have a daily loss limit unless I’m up a considerable amount then I’ll put it on there, but that’s only if like a runner ran like a 1 to 10 RR or something insane

I don’t have one. I will never have one if I made any course it would be around the mindset because the mindset is what was the real key for me being profitable truly. It’s the manifestation aspect. It has nothing to do with trading. It has everything to do with self-concept and your belief about money and making money reading candles on a chart and reading overflow and get Data Gamma Vanna, positive gamma negative gamma CBD divergence is delta‘s standard deviations, etc. none of that shit is hard but your belief about withdrawing the money and putting it in your bank account and keeping it in rinsing and repeating and doing it over and over and over again and the reason you can’t follow a set of rules or stick to a system or jump from strategy strategy is because of a deep proceeded wound that is in yourself. Once you can heal that and be completely OK with who you are what you are doing where you are going in the belief within yourself of the money you are capable of making I promise you, I swear to you, your entire life will open up and things will change for you in ways. You have never seen that is the true sauce. It isn’t learning a system. It isn’t copying traitors. It isn’t signal boarding. It is strictly believing in a real reality that doesn’t exist yet, but acting as if you have that but that’s profitability whether that’s rinsing these proper whether that’s being a live trait or whatever it is that you want you need to identify that and then find the blocks that are inhibiting you from getting there and then once you find those blocks, heal them and replace them with the opposite thinking and that will yield you in ROY you cannot even qualify, brother

It’s not a matter of states trying to block interstate commerce. S3 doesn’t legalize cannabis, and under the new final rule the feds explicitly empower the state regulatory frameworks. You still won’t be able to legally obtain cannabis in the seven or so states where it’s still fully illegal, for example.
Note: excluding non-intoxicating hemp/CBD from this discussion.